PET Imaging of Hepatocellular Carcinoma Using ZD2-(⁶⁸Ga-NOTA)

References

• NIH. Action Plan for Liver Disease Research: A Report of the Liver Disease Subcommittee of the Digestive Diseases Interagency Coordinating Committee. NIH Publication; 2004.
   Google Scholar
• Bruix J, Sherman M. Practice guidelines committee AAftSoLD. management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–1236. doi:10.1002/hep.20933
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee JM, Kim SJ, et al. Enhancement patterns of hepatocellular carcinomas on multiphasic multidetector row CT: comparison with pathological differentiation. Br J Radiol. 2012;85(1017):e573–e583. doi:10.1259/bjr/86767895
   PubMed Web of Science ®Google Scholar
• Jeng LB, Changlai SP, Shen YY, Lin CC, Tsai CH, Kao CH. Limited value of 18F-2-deoxyglucose positron emission tomography to detect hepatocellular carcinoma in hepatitis B virus carriers. Hepato-Gastroenterology. 2003;50(54):2154–2156.
   PubMedGoogle Scholar
• Han Z, Zhou Z, Shi X, et al. EDB fibronectin specific peptide for prostate cancer targeting. Bioconjug Chem. 2015;26(5):830–838. doi:10.1021/acs.bioconjchem.5b00178
   PubMed Web of Science ®Google Scholar
• Han Z, Sergeeva O, Roelle S, et al. Preparation and evaluation of ZD2 Peptide (64) Cu-DOTAConjugate as a positron emission tomography probe for detection and characterization of prostate cancer. ACS Omega. 2019;4(1):1185–1190.
   PubMed Web of Science ®Google Scholar
• Ayat NR, Vaidya A, Yeung GA, et al. Effective MR molecular imaging of triple negative breast cancer with an EDB-fibronectin-specific contrast agent at reduced doses. Front Oncol. 2019;9:1351.
   PubMed Web of Science ®Google Scholar
• Gao S, Qin J, Sergeeva O, et al. Synthesis and assessment of ZD2-((68) Ga-NOTA)specific to extradomain B fibronectin in tumor microenvironment for PET imaging of pancreatic cancer. Am J Nucl Med Mol Imaging. 2019;9(5):216–229.
   PubMed Web of Science ®Google Scholar
• Sauer S, Erba PA, Petrini M, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood. 2009;113(10):2265–2274.
   PubMed Web of Science ®Google Scholar
• Wagner K, Schulz P, Scholz A, Wiedenmann B, Menrad A. The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. Clin Cancer Res. 2008;14(15):4951–4960. doi:10.1158/1078-0432.CCR-08-0157
   PubMed Web of Science ®Google Scholar
• Antoon JW, Lai R, Struckhoff AP, et al. Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance. Sci Rep. 2012;2:539. doi:10.1038/srep00539
   PubMed Web of Science ®Google Scholar
• Wang R, Cheng L, Xia J, Wang Z, Wu Q, Wang Z. Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1alpha in pancreatic cancer cells. Curr Cancer Drug Targets. 2014;14(4):407–417. doi:10.2174/1568009614666140226114015
   PubMed Web of Science ®Google Scholar
• Parvani JG, Gujrati MD, Mack MA, Schiemann WP, Lu ZR. Silencing beta3 integrin by targeted ECO/siRNA nanoparticles inhibits EMT and metastasis of triple-negative breast cancer. Cancer Res. 2015;75(11):2316–2325. doi:10.1158/0008-5472.CAN-14-3485
   PubMed Web of Science ®Google Scholar
• Vaidya A, Wang H, Qian V, Gilmore H, Lu ZR. Overexpression of extradomain-B fibronectin is associated with invasion of breast cancer cells. Cells. 2020;9(8):1826.
   PubMed Web of Science ®Google Scholar
• Vaidya A, Ayat N, Buford M, et al. Noninvasive assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin. Theranostics. 2020;10(24):11127–11143. doi:10.7150/thno.47448
   PubMed Web of Science ®Google Scholar
• Hesse E, Musholt PB, Potter E, et al. Oncofoetal fibronectin--a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma. Br J Cancer. 2005;93(5):565–570. doi:10.1038/sj.bjc.6602741
   PubMed Web of Science ®Google Scholar
• Kaspar M, Zardi L, Neri D. Fibronectin as target for tumor therapy. Int J Cancer. 2006;118(6):1331–1339. doi:10.1002/ijc.21677
   PubMed Web of Science ®Google Scholar
• Mhawech P, Dulguerov P, Assaly M, Ares C, Allal AS. EB-D fibronectin expression in squamous cell carcinoma of the head and neck. Oral Oncol. 2005;41(1):82–88. doi:10.1016/j.oraloncology.2004.07.003
   PubMed Web of Science ®Google Scholar
• Richter P, Junker K, Franz M, et al. IIICS de novo glycosylated fibronectin as a marker for invasiveness in urothelial carcinoma of the urinary bladder (UBC). J Cancer Res Clin Oncol. 2008;134(10):1059–1065. doi:10.1007/s00432-008-0390-6
   PubMed Web of Science ®Google Scholar
• Santimaria M, Moscatelli G, Viale GL, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res. 2003;9(2):571–579.
   PubMed Web of Science ®Google Scholar
• Kaczmarek J, Castellani P, Nicolo G, Spina B, Allemanni G, Zardi L. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer. 1994;59(1):11–16. doi:10.1002/ijc.2910590104
   PubMed Web of Science ®Google Scholar
• Nam JM, Onodera Y, Bissell MJ, Park CC. Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin. Cancer Res. 2010;70(13):5238–5248. doi:10.1158/0008-5472.CAN-09-2319
   PubMed Web of Science ®Google Scholar
• Loridon-Rosa B, Vielh P, Matsuura H, Clausen H, Cuadrado C, Burtin P. Distribution of oncofetal fibronectin in human mammary tumors: immunofluorescence study on histological sections. Cancer Res. 1990;50(5):1608–1612.
   PubMed Web of Science ®Google Scholar
• Koukoulis GK, Howeedy AA, Korhonen M, Virtanen I, Gould VE. Distribution of tenascin, cellular fibronectins and integrins in the normal, hyperplastic and neoplastic breast. J Submicrosc Cytol Pathol. 1993;25(2):285–295.
   PubMed Web of Science ®Google Scholar
• Matsumoto E, Yoshida T, Kawarada Y, Sakakura T. Expression of fibronectin isoforms in human breast tissue: production of extra domain A+/extra domain B+ by cancer cells and extra domain A+ by stromal cells. Jpn J Cancer Res. 1999;90(3):320–325. doi:10.1111/j.1349-7006.1999.tb00750.x
   PubMedGoogle Scholar
• Gould VE, Koukoulis GK, Virtanen I. Extracellular matrix proteins and their receptors in the normal, hyperplastic and neoplastic breast. Cell Differ Dev. 1990;32(3):409–416. doi:10.1016/0922-3371(90)90057-4
   PubMedGoogle Scholar
• Korba BE, Wells FV, Baldwin B, et al. Hepatocellular carcinoma in woodchuck hepatitis virus-infected woodchucks: presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections. Hepatology. 1989;9(3):461–470.
   PubMed Web of Science ®Google Scholar
• Midulla M, Verma R, Pignatelli M, Ritter MA, Courtenay-Luck NS, George AJ. Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells. Cancer Res. 2000;60(1):164–169.
   PubMed Web of Science ®Google Scholar
• Salem N, Kuang Y, Wang F, Maclennan GT, Lee Z. PET imaging of hepatocellular carcinoma with 2-deoxy-2[18F]fluoro-D-glucose, 6-deoxy-6[18F] fluoro-D-glucose, [1-11C]-acetate and [N-methyl-11C]-choline. Q J Nucl Med Mol Imaging. 2009;53(2):144–156.
   PubMed Web of Science ®Google Scholar
• Kuang Y, Salem N, Tian H, et al. Imaging lipid synthesis in hepatocellular carcinoma with [methyl-11c]choline: correlation with in vivo metabolic studies. J Nucl Med. 2011;52(1):98–106. doi:10.2967/jnumed.110.080366
   PubMed Web of Science ®Google Scholar
• Salem N, Kuang Y, Corn D, et al. [(Methyl)1-(11)c]-acetate metabolism in hepatocellular carcinoma. Mol Imaging Biol. 2011;13(1):140–151. doi:10.1007/s11307-010-0308-y
   PubMed Web of Science ®Google Scholar
• Kuang Y, Wang F, Corn DJ, Tian H, Lee Z. Metabolism of radiolabeled methionine in hepatocellular carcinoma. Mol Imaging Biol. 2014;16(1):44–52. doi:10.1007/s11307-013-0678-z
   PubMed Web of Science ®Google Scholar
• Kolthammer JA, Corn DJ, Tenley N, et al. PET imaging of hepatocellular carcinoma with 18F-fluoroethylcholine and 11C-choline. Eur J Nucl Med Mol Imaging. 2011;38(7):1248–1256. doi:10.1007/s00259-011-1743-y
   PubMed Web of Science ®Google Scholar
• Kuang Y, Salem N, Corn DJ, et al. Transport and metabolism of radiolabeled choline in hepatocellular carcinoma. Mol Pharm. 2010;7(6):2077–2092. doi:10.1021/mp1001922
   PubMedGoogle Scholar
• Kuang Y, Salem N, Wang F, Schomisch SJ, Chandramouli V, Lee Z. A colorimetric assay method to measure acetyl-CoA synthetase activity: application to woodchuck model of hepatitis virus-induced hepatocellular carcinoma. J Biochem Biophys Methods. 2007;70(4):649–655. doi:10.1016/j.jbbm.2007.02.008
   PubMedGoogle Scholar
• Kuang Y, Schomisch SJ, Chandramouli V, Lee Z. Hexokinase and glucose-6-phosphatase activity in woodchuck model of hepatitis virus-induced hepatocellular carcinoma. Comp Biochem Physiol C Toxicol Pharmacol. 2006;143(2):225–231. doi:10.1016/j.cbpc.2006.02.005
   PubMed Web of Science ®Google Scholar
• Kuang Y, Wang F, Corn DJ, Tian H, Lee Z. In vitro characterization of uptake mechanism of L-[methyl-(3)H]-methionine in hepatocellular carcinoma. Mol Imaging Biol. 2014;16(4):459–468. doi:10.1007/s11307-014-0720-9
   PubMed Web of Science ®Google Scholar
• Salem N, MacLennan GT, Kuang Y, et al. Quantitative evaluation of 2-deoxy-2[F-18]fluoro-D-glucose-positron emission tomography imaging on the woodchuck model of hepatocellular carcinoma with histological correlation. Mol Imaging Biol. 2007;9(3):135–143. doi:10.1007/s11307-007-0092-5
   PubMed Web of Science ®Google Scholar
• Andres Ibarra R, Abbas R, Kombu RS, et al. Disturbances in the glutathione/ophthalmate redox buffer system in the woodchuck model of hepatitis virus-induced hepatocellular carcinoma. HPB Surg. 2011;2011:789323. doi:10.1155/2011/789323
   PubMedGoogle Scholar
• Gerin JL, Cote PJ, Korba BE, Tennant BC. Hepadnavirus-induced liver cancer in woodchucks. Cancer Detect Prev. 1989;14(2):227–229.
   PubMedGoogle Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi:10.1186/s13059-014-0550-8
   PubMed Web of Science ®Google Scholar
• Fletcher SP, Chin DJ, Ji Y, et al. Transcriptomic analysis of the woodchuck model of chronic hepatitis B. Hepatology. 2012;56(3):820–830. doi:10.1002/hep.25730
   PubMed Web of Science ®Google Scholar
• Han Z, Li Y, Roelle S, et al. Targeted contrast agent specific to an oncoprotein in tumor microenvironment with the potential for detection and risk stratification of prostate cancer with MRI. Bioconjug Chem. 2017;28(4):1031–1040. doi:10.1021/acs.bioconjchem.6b00719
   PubMed Web of Science ®Google Scholar
• Julyan PJ, Taylor JH, Hastings DL, Williams HA, Zweit J. SUVpeak: a new parameter for quantification of uptake in FDG PET. Nucl Med Commun. 2004;25(4):407. doi:10.1097/00006231-200404000-00040
   Google Scholar
• Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50S. doi:10.2967/jnumed.108.057307
   PubMed Web of Science ®Google Scholar
• Scarpino S, Stoppacciaro A, Pellegrini C, et al. Expression of EDA/EDB isoforms of fibronectin in papillary carcinoma of the thyroid. J Pathol. 1999;188(2):163–167. doi:10.1002/(SICI)1096-9896(199906)188:2<163::AID-PATH335>3.0.CO;2-1
   PubMed Web of Science ®Google Scholar
• Attieh Y, Clark AG, Grass C, et al. Cancer-associated fibroblasts lead tumor invasion through integrin-beta3-dependent fibronectin assembly. J Cell Biol. 2017;216(11):3509–3520. doi:10.1083/jcb.201702033
   PubMed Web of Science ®Google Scholar
• Erdogan B, Ao M, White LM, et al. Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin. J Cell Biol. 2017;216(11):3799–3816. doi:10.1083/jcb.201704053
   PubMed Web of Science ®Google Scholar
• Mhawech-Fauceglia P, Wang D, Samrao D, et al. Clinical implications of marker expression of carcinoma-associated fibroblasts (CAFs) in patients with epithelial ovarian carcinoma after treatment with neoadjuvant chemotherapy. Cancer Microenvir. 2014;7(1–2):33–39. doi:10.1007/s12307-013-0140-4
   PubMedGoogle Scholar
• Conte GD, Tosi D, Fasolo A, et al. A Phase I trial of antifibronecitin 131I-L19-small immunoprotein (L19-SIP) in solid tumors and lymphoproliferative disease. J Clin Oncol. 2008;26(15_suppl):2575. doi:10.1200/jco.2008.26.15_suppl.2575
   Web of Science ®Google Scholar
• Berndorff D, Borkowski S, Moosmayer D, et al. Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. J Nucl Med. 2006;47(10):1707–1716.
   PubMed Web of Science ®Google Scholar
• Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–461. doi:10.1002/jcc.21334
   PubMed Web of Science ®Google Scholar
• Giesel FL, Kratochwil C, Lindner T, et al. (68)Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60(3):386–392. doi:10.2967/jnumed.118.215913
   PubMed Web of Science ®Google Scholar
• Kratochwil C, Flechsig P, Lindner T, et al. (68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60(6):801–805. doi:10.2967/jnumed.119.227967
   PubMed Web of Science ®Google Scholar
• Chayanupatkul M, Omino R, Mittal S, et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol. 2017;66(2):355–362. doi:10.1016/j.jhep.2016.09.013
   PubMed Web of Science ®Google Scholar
• Tennant BC, Toshkov IA, Peek SF, et al. Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology. 2004;127(5 Suppl 1):S283–S293. doi:10.1053/j.gastro.2004.09.043
   PubMedGoogle Scholar